You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
特一藥業(002728.SZ):止咳寶片目前也是新冠病毒感染導致咳嗽的推薦止咳藥
格隆匯 08-11 17:57

格隆匯8月11日丨有投資者向特一藥業(002728.SZ)提問,“新冠病毒變異株EG.5在美快速流行,新型冠狀病毒感染病例激增。法國衞生部門也注意到,與新冠感染有關的住院人數最近有所增加,EG.5毒株的變種在法國新增病例中佔多數。請問我們需要購買公司哪些藥物來應對eg5新冠?公司的新冠藥藥效比其他公司好,公司可以考慮上個新冠治療防護以及新冠後期身體調養套餐嗎?”

特一藥業回覆稱,公司藥品品類豐富,產品涵蓋止咳、退熱、抗生素、抗病毒藥、消化系統等全類別。針對感染新型冠狀病毒後出現的咳嗽、咽喉痛、發燒及腸胃不適等症狀,公司的產品用於止咳化痰方面的有止咳寶片、小兒止咳糖漿、小兒咳喘靈顆粒、羧甲司坦片;治療咽喉痛的藥物有蒲地藍消炎片、咽炎片、複方魚腥草片、穿心蓮片;退燒藥方面,公司有對乙酰氨基酚片、布洛芬片、雙氯芬酸鈉腸溶片;腸胃用藥方面,公司有鋁碳酸鎂咀嚼片、楓蓼腸胃康片、蒙脱石散等。特別是公司核心產品止咳寶片,有一百多年曆史,在清代末期就享有盛譽,具有“宣肺祛痰、止咳平喘”之功效。經臨牀總結有三大特點:一是對各類型的慢性咳嗽有顯著效果,對止咳、化痰、平喘療效十分明顯,臨控+顯效率為73%,總有效率為93%;二是毒副作用低,療程短、見效快、服藥方便;三是對虛寒型和痰濕型咳喘治療效果最好,總有效率分別是100%及95%。止咳寶片目前也是新冠病毒感染導致咳嗽的推薦止咳藥。費者可根據實際需要自行選購藥物做好自身防護。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account